Novan’s Phase 2 SB206 Study Published in Journal of American Academy of Dermatology

- October 8th, 2019

The company’s results from its Phase 2 SB206 trial were published in the Journal of the American Academy of Dermatology.

Novan  (NASDAQ:NOVN) has announced that its Phase 2 molluscum study has been published in the Journal of the American Academy of Dermatology.

As quoted in the press release:

In this Phase 2 study, SB206 demonstrated clinical efficacy with a favorable safety profile.

“The publication of this Phase 2 study through a prestigious platform such as JAAD underscores Novan’s innovative nitric-oxide technology and provides exposure to the results that supported our decision to progress into a Phase 3 molluscum program. There remains an unmet medical need for an efficacious and well-tolerated treatment that can be applied at home by patients or caregivers,” commented Tomoko Maeda-Chubachi, M.D., Ph.D., Novan’s Vice President of Medical Dermatology. Dr. Maeda-Chubachi further commented, “We look forward to reporting out the results from our Phase 3 B-SIMPLE pivotal program in the near future.”

Title“Efficacy and Tolerability of an Investigational Nitric Oxide-releasing Topical Gel in Patients With Molluscum Contagiosum: A Randomized Clinical Trial”
Authors: Adelaide A. Hebert, Elaine C. Siegfried, Todd Durham, Emily N. de León, Teresa Reams, Elizabeth Messersmith, Tomoko Maeda-Chubachi
PublicationJournal of the American Academy of Dermatology (Available online 03 October 2019), doi: [Epub ahead of print]

Novan continues to target top line results from the ongoing Phase 3 “B-SIMPLE” (Berdazimer Sodium In Molluscum Patients with Lesions) pivotal trials with SB206 for the treatment of molluscum no later than early in the first quarter of 2020.

Click here to read the full press release.

Is the biotech market the perfect mesh between the technology and pharmaceutical market?

Read our FREE outlook report below!

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply